This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

REAL-WORLD EXPERIENCE, ALL AROUND THE WORLD

The persons depicted are models for illustrative purposes only.

More than 52 million doses of BEXSERO have been distributed worldwide since 2015.1

 

BEXSERO is approved in 40+ countries, including Canada, Australia, and much of Europe.2

 

BEXSERO was used in response to outbreaks on major college campuses, including3:

  • Princeton University4
  • University of Wisconsin–Madison5
See a real college student’s MenB survival story

> WATCH RAYNA’S STORY

MenB=meningococcal serogroup B. 

Indication 

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years. 

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

 

The persons depicted are models for illustrative purposes only.

More than 52 million doses of BEXSERO have been distributed worldwide since 2015.1

 

BEXSERO is approved in 40+ countries, including Canada, Australia, and much of Europe.2

 

BEXSERO was used in response to outbreaks on major college campuses, including3:

  • Princeton University4
  • University of Wisconsin–Madison5
See a real college student’s MenB survival story

> WATCH RAYNA’S STORY

MenB=meningococcal serogroup B.

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years. 

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

 

References

  1. Data on file. 2017N320400_05. GSK.
  2. Data on file. 2016N297580_02. GSK.
  3. Prescribing Information for BEXSERO.
  4. McNamara LA, Shumate AM, Johnsen P, et al. First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak. Pediatrics. 2015;135(5):798-804. doi:10.1542/peds.2014-4015.
  5. Mbaeyi SA, Blain A, Whaley MJ, et al. Meningococcal disease among college-aged young adults: 2014-2016. Pediatrics. 2019;143(1):e20182130. doi:10.1542/peds.2019-0342.

Indication

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

Important Safety Information for BEXSERO

  • BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
  • Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions
  • Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
  • Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
  • Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with BEXSERO
  • Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.

Trademarks are property of their respective owners.